Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Annalisa Comandatore

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6930-0595; OpenAlex author ID A5091428659. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
71
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 4 papers · 2025: 5 papers · 2026: 5 papers

Papers 20

  1. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  2. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  3. The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance. Co-author DOI 10.1016/j.drup.2026.101408↗
  4. Proteomics of Extracellular Vesicles Derived from Primary Cells of Pancreatic Ductal Adenocarcinoma Patients Identifies Ribosomal Proteins Associated with Surv… Co-author DOI 10.1021/acs.jproteome.6c00168↗
  5. Young Age Is Associated with Improved Survival After Resection of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/life16091499↗
  6. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  7. The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC. Co-author DOI 10.1016/j.semcancer.2025.05.004↗
  8. Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors. Co-author DOI 10.1016/j.semcancer.2025.06.001↗
  9. Navigating the paradox of senescence and chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.06.007↗
  10. Raman spectroscopy based diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-98122-9↗
  11. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  12. Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study. First author DOI 10.1093/bjsopen/zrad119↗
  13. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03090-z↗
  14. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target. Co-author DOI 10.7150/ijbs.92671↗
  15. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Co-author DOI 10.1001/jamanetworkopen.2023.31197↗
  16. Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in p… First author DOI 10.1016/j.semcancer.2023.11.003↗
  17. Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/cancers15030628↗
  18. "Depart from evil, and do good": Turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2022.103659↗
  19. Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. Co-author DOI 10.3390/diagnostics12020286↗
  20. Organotypic-liver slide culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approa… First author DOI 10.1080/17425255.2021.1925646↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Luca Morelli · 16 shared papers, 2021–2026 · strength 3.35
  2. Elisa Giovannetti · 15 shared papers, 2021–2026 · strength 3.06
  3. Ingrid Garajová · 8 shared papers, 2022–2026 · strength 1.51
  4. Geert Kazemier M · 5 shared papers, 2023–2026 · strength 0.89
  5. Benoît Immordino · 4 shared papers, 2022–2026 · strength 0.81
  6. Mahrou Vahabi · 3 shared papers, 2023–2026 · strength 0.71
  7. Lenka N.C. Boyd · 3 shared papers, 2023–2024 · strength 0.49
  8. Jisce R. Puik · 3 shared papers, 2023–2024 · strength 0.48
  9. Marc G. Besselink · 3 shared papers, 2023–2024 · strength 0.48
  10. Adam Enver Frampton · 3 shared papers, 2023–2024 · strength 0.48
  11. Rita Balsano · 3 shared papers, 2022–2024 · strength 0.48
  12. Mjriam Capula · 3 shared papers, 2022–2023 · strength 0.48
  13. Daniele Campa · 2 shared papers, 2025 · strength 0.41
  14. Gregorio Di Franco · 2 shared papers, 2024–2025 · strength 0.37
  15. Manuel Gentiluomo · 2 shared papers, 2024–2025 · strength 0.37
  16. I Gede Putu Supadmanaba · 2 shared papers, 2021–2024 · strength 0.35
  17. Asia Botto · 1 shared paper, 2026 · strength 0.33
  18. Liam Andrew McDonnell · 1 shared paper, 2026 · strength 0.33
  19. Mafalda Angelica Rocco · 1 shared paper, 2026 · strength 0.33
  20. Rutger‐Jan Swijnenburg · 2 shared papers, 2024 · strength 0.33
  21. Laura L. Meijer · 2 shared papers, 2023–2024 · strength 0.32
  22. Tessa Y. S. Le Large · 2 shared papers, 2023–2024 · strength 0.32
  23. Hanneke W.M. van Laarhoven · 2 shared papers, 2023–2024 · strength 0.32
  24. Gianmarco Lazzini · 1 shared paper, 2025 · strength 0.28
  25. Mario D’Acunto · 1 shared paper, 2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.